Compare TLYS & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLYS | RCEL |
|---|---|---|
| Founded | 1982 | N/A |
| Country | United States | United States |
| Employees | N/A | 226 |
| Industry | Clothing/Shoe/Accessory Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.1M | 146.2M |
| IPO Year | 2011 | N/A |
| Metric | TLYS | RCEL |
|---|---|---|
| Price | $4.20 | $7.73 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $2.00 | ★ $7.88 |
| AVG Volume (30 Days) | 134.9K | ★ 220.7K |
| Earning Date | 06-03-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.66 | $17.17 |
| Revenue Next Year | $1.74 | $49.82 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.14 | $3.22 |
| 52 Week High | $5.90 | $7.12 |
| Indicator | TLYS | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 54.38 |
| Support Level | $3.60 | $3.92 |
| Resistance Level | $4.59 | $5.18 |
| Average True Range (ATR) | 0.22 | 0.30 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 72.15 | 44.50 |
Tilly's Inc works as a specialty retailer of casual apparel, footwear, and accessories for young men, young women, boys, and girls. It offers an unparalleled selection of relevant brands, styles, colors, sizes, and price points. It delivers branded fashion and core styles for tops, outerwear, bottoms, and dresses. It also provides backpacks, hats, sunglasses, headphones, handbags, watches, and jewelry. It markets its products under the brand names of Vans, RVCA, Adidas, Nike SB, and Hurley, among others. It operates its stores in malls, lifestyle centers, power centers, community centers, outlet centers, street-front locations, and also through e-commerce.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.